ReviewDrugs2021
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Reversible Coordination Modes in Piperazine-Based Ru(II)-p-Cymene Acylthiourea Complexes: Modulating DNA Groove Binding for Selective Antimelanoma Activity.ChemMedChem · 2026Article
- Evaluation of the Effects of Nicardipine on Entrectinib Metabolism in vitro and in Rats.European journal of drug metabolism and pharmacokinetics · 2026Article
- Safety profile of entrectinib in NSCLC: Multi-source pharmacovigilance analysis using FAERS and JADER.PloS one · 2026Article
- Taletrectinib in ROS1-positive NSCLC: bridging clinical trials and real-world practice.Annals of medicine and surgery (2012) · 2025Article
- In silico & in vitro approaches suggest osteoclastogenesis induction underlying fractures in Entrectinib-treated children.Archives of toxicology · 2025Article
- RNA splicing: Novel star in pulmonary diseases with a treatment perspective.Acta pharmaceutica Sinica. B · 2025Review
- [A Case Report of Lung Adenocarcinoma with EGFR G719A Mutation and LMNA-NTRK1 Fusion].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- MicroRNAs and lung cancer: overview of essential pathways and somatic mutations in cancer progression.Frontiers in oncology · 2025Review
- ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report.Frontiers in cardiovascular medicine · 2025Article
- Bridging inflammation and venous thrombosis: the NLRP3 inflammasome connection.Frontiers in cardiovascular medicine · 2025Review
- Case Report: Therapeutic biopsy guided targeted therapy improves visual acuity and prolongs survival in bilateral uveal metastases as the initial presentation of lung adenocarcinoma.Frontiers in medicine · 2025Article
- Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways.Frontiers in pharmacology · 2025Article
- Unveiling Indazole: Novel Synthetic Pathways and Biological Potentials.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Review
- Targeting PYK2, entrectinib allays anterior subcapsular cataracts in mice by regulating TGFβ2 signaling pathway.Molecular medicine (Cambridge, Mass.) · 2024Article
- Article
- Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non-small cell lung cancer patients.Cancer medicine · 2024Article
- Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).Current oncology (Toronto, Ont.) · 2024Article
- Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024Review
- From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.Frontiers in pharmacology · 2024Article
- Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7.Cell reports. Medicine · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Entrectinib (Rozlytrek
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.